WWW.DISSERTATION.XLIBX.INFO
FREE ELECTRONIC LIBRARY - Dissertations, online materials
 
<< HOME
CONTACTS



Pages:     | 1 | 2 || 4 | 5 |   ...   | 9 |

«Suicidality and Antidepressant Drugs Antidepressants increased the risk compared to placebo of suicidal thinking and behavior (suicidality) in ...»

-- [ Page 3 ] --

The following symptoms, anxiety, agitation, panic attacks, insomnia, irritability, hostility, aggressiveness, impulsivity, akathisia (psychomotor restlessness), hypomania, and mania, have been reported in adult and pediatric patients being treated with antidepressants for major depressive disorder as well as for other indications, both psychiatric and nonpsychiatric.

Although a causal link between the emergence of such symptoms and either the worsening of depression and/or the emergence of suicidal impulses has not been established, there is concern that such symptoms may represent precursors to emerging suicidality.

Consideration should be given to changing the therapeutic regimen, including possibly discontinuing the medication, in patients whose depression is persistently worse, or who are experiencing emergent suicidality or symptoms that might be precursors to worsening depression or suicidality, especially if these symptoms are severe, abrupt in onset, or were not part of the patient's presenting symptoms.

If the decision has been made to discontinue treatment, medication should be tapered, as rapidly as is feasible, but with recognition that abrupt discontinuation can be associated with certain symptoms (see PRECAUTIONS and DOSAGE AND ADMINISTRATION, Discontinuation of Treatment with Effexor XR, for a description of the risks of discontinuation of Effexor XR).

Families and caregivers of patients being treated with antidepressants for major depressive disorder or other indications, both psychiatric and nonpsychiatric, should be alerted about the need to monitor patients for the emergence of agitation, irritability, unusual changes in behavior, and the other symptoms described above, as well as the emergence of suicidality, and to report such symptoms immediately to health care providers. Such monitoring should include daily observation by families and caregivers. Prescriptions for Effexor XR should be written for the smallest quantity of capsules consistent with good patient management, in order to reduce the risk of overdose.

10 Reference ID: 3537473 Screening Patients for Bipolar Disorder A major depressive episode may be the initial presentation of bipolar disorder. It is generally believed (though not established in controlled trials) that treating such an episode with an antidepressant alone may increase the likelihood of precipitation of a mixed/manic episode in patients at risk for bipolar disorder. Whether any of the symptoms described above represent such a conversion is unknown. However, prior to initiating treatment with an antidepressant, patients with depressive symptoms should be adequately screened to determine if they are at risk for bipolar disorder; such screening should include a detailed psychiatric history, including a family history of suicide, bipolar disorder, and depression. It should be noted that Effexor XR is not approved for use in treating bipolar depression.

Serotonin Syndrome:

The development of a potentially life-threatening serotonin syndrome has been reported with SNRIs and SSRIs, including Effexor XR, alone but particularly with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, and St. John's Wort) and with drugs that impair metabolism of serotonin (in particular, MAOIs, both those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).

Serotonin syndrome symptoms may include mental status changes (e.g., agitation, hallucinations, delirium, and coma), autonomic instability (e.g., tachycardia, labile blood pressure, dizziness, diaphoresis, flushing, hyperthermia), neuromuscular symptoms (e.g., tremor, rigidity, myoclonus, hyperreflexia, incoordination), seizures, and/or gastrointestinal symptoms (e.g., nausea, vomiting, diarrhea). Patients should be monitored for the emergence of serotonin syndrome.

The concomitant use of Effexor XR with MAOIs intended to treat psychiatric disorders is contraindicated. Effexor XR should also not be started in a patient who is being treated with MAOIs such as linezolid or intravenous methylene blue. All reports with methylene blue that provided information on the route of administration involved intravenous administration in the dose range of 1 mg/kg to 8 mg/kg. No reports involved the administration of methylene blue by other routes (such as oral tablets or local tissue injection) or at lower doses. There may be circumstances when it is necessary to initiate treatment with a MAOI such as linezolid or intravenous methylene blue in a patient taking Effexor XR. Effexor XR should be discontinued before initiating treatment with the MAOI (see CONTRAINDICATIONS and DOSAGE AND ADMINISTRATION).

If concomitant use of Effexor XR with other serotonergic drugs, including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, buspirone, tryptophan, and St. John's Wort is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases.

Treatment with Effexor XR and any concomitant serotonergic agents should be discontinued immediately if the above events occur and supportive symptomatic treatment should be initiated.

11 Reference ID: 3537473 Angle-Closure Glaucoma: The pupillary dilation that occurs following use of many antidepressant drugs including Effexor XR may trigger an angle closure attack in a patient with anatomically narrow angles who does not have a patent iridectomy.





Sustained Hypertension Effexor XR treatment is associated with sustained hypertension (defined as treatment-emergent supine diastolic blood pressure (SDBP) ≥90 mm Hg and ≥10 mm Hg above baseline for 3 consecutive on-therapy visits (see Table 2).

An analysis for patients in Effexor (immediate release) studies meeting criteria for sustained hypertension revealed a dose-dependent increase in the incidence of sustained hypertension for Effexor (immediate release) (see Table 3).

An insufficient number of patients received mean doses of Effexor XR over 300 mg/day to fully evaluate the incidence of sustained increases in blood pressure at these higher doses.

Table 2 Number (%) of Sustained Elevations in SDBP in Effexor XR Premarketing Studies by

–  –  –

In premarketing major depressive disorder studies, 0.7% (5/705) of the Effexor XR-treated patients discontinued treatment because of elevated blood pressure. Among these patients, most of the blood pressure increases were in a modest range (12 to 16 mm Hg, SDBP). In premarketing GAD studies up to 8 weeks and up to 6 months, 0.7% (10/1381) and 1.3% (7/535) of the Effexor XR-treated patients, respectively, discontinued treatment because of elevated blood pressure. Among these patients, most of the blood pressure increases were in a modest range (12 to 25 mm Hg, SDBP up to 8 weeks; 8 to 28 mm Hg up to 6 months). In premarketing Social Anxiety Disorder studies up to 6 months, 0.6% (5/771) of the 12 Reference ID: 3537473 Effexor XR-treated patients discontinued treatment because of elevated blood pressure. In these patients, the blood pressure increases were modest (1-24 mm Hg, SDBP). In premarketing panic disorder studies up to 12 weeks, 0.5% (5/1001) of the Effexor XR-treated patients discontinued treatment because of elevated blood pressure. In these patients, the blood pressure increases were in a modest range (7 to 19 mm Hg, SDBP).

Sustained increases of SDBP could have adverse consequences. Cases of elevated blood pressure requiring immediate treatment have been reported in post marketing experience. Pre-existing hypertension should be controlled before treatment with venlafaxine. It is recommended that patients receiving Effexor XR have regular monitoring of blood pressure. For patients who experience a sustained increase in blood pressure while receiving venlafaxine, either dose reduction or discontinuation should be considered.

Elevations in Systolic and Diastolic Blood Pressure In placebo-controlled premarketing studies, there were changes in mean blood pressure (see Table 4 for mean changes in supine systolic and supine diastolic blood pressure). Across most indications, a dose-related increase in supine systolic and diastolic blood pressure was evident in Effexor XR-treated patients.

Table 4 Final On-Therapy Mean Changes from Baseline in Supine Systolic and Diastolic Blood Pressure (mm Hg) Results by Indication, Study Duration, and Dose in Placebo-Controlled Trials

–  –  –

13 Reference ID: 3537473 Table 4 Final On-Therapy Mean Changes from Baseline in Supine Systolic and Diastolic Blood Pressure (mm Hg) Results by Indication, Study Duration, and Dose in Placebo-Controlled Trials

–  –  –

PRECAUTIONS

General Discontinuation of Treatment with Effexor XR Discontinuation symptoms have been systematically evaluated in patients taking venlafaxine, to include prospective analyses of clinical trials in Generalized Anxiety Disorder and retrospective surveys of trials in major depressive disorder, and Social Anxiety Disorder. Abrupt discontinuation or dose reduction of venlafaxine at various doses has been found to be associated with the appearance of new symptoms, the frequency of which increased with increased dose level and with longer duration of treatment. Reported symptoms include agitation, anorexia, anxiety, confusion, impaired coordination and balance, diarrhea, dizziness, dry mouth, dysphoric mood, fasciculation, fatigue, flu-like symptoms, headaches, hypomania, insomnia, nausea, nervousness, nightmares, sensory disturbances (including shock-like electrical sensations), somnolence, sweating, tremor, vertigo, and vomiting.

During marketing of Effexor XR, other SNRIs (Serotonin and Norepinephrine Reuptake Inhibitors), and SSRIs (Selective Serotonin Reuptake Inhibitors), there have been spontaneous reports of adverse events occurring upon discontinuation of these drugs, particularly when abrupt, including the following: dysphoric mood, irritability, agitation, dizziness, sensory disturbances (e.g. paresthesias such as electric shock sensations), anxiety, confusion, headache, 14 Reference ID: 3537473 lethargy, emotional lability, insomnia, hypomania, tinnitus, and seizures. While these events are generally self-limiting, there have been reports of serious discontinuation symptoms.

Patients should be monitored for these symptoms when discontinuing treatment with Effexor XR. A gradual reduction in the dose rather than abrupt cessation is recommended whenever possible. If intolerable symptoms occur following a decrease in the dose or upon discontinuation of treatment, then resuming the previously prescribed dose may be considered.

Subsequently, the physician may continue decreasing the dose but at a more gradual rate (see

DOSAGE AND ADMINISTRATION).

Insomnia and Nervousness Treatment-emergent insomnia and nervousness were more commonly reported for patients treated with Effexor XR (venlafaxine hydrochloride) extended-release capsules than with placebo in pooled analyses of short-term major depressive disorder, GAD, Social Anxiety Disorder, and panic disorder studies, as shown in Table 5.

–  –  –

Insomnia and nervousness each led to drug discontinuation in 0.9% of the patients treated with Effexor XR in major depressive disorder studies.

In GAD trials, insomnia and nervousness led to drug discontinuation in 3% and 2%, respectively, of the patients treated with Effexor XR up to 8 weeks and 2% and 0.7%, respectively, of the patients treated with Effexor XR up to 6 months.

In Social Anxiety Disorder trials, insomnia and nervousness led to drug discontinuation in 2% and 1%, respectively, of the patients treated with Effexor XR up to 12 weeks and 2% and 3% respectively, of the patients treated with Effexor XR up to 6 months.

In panic disorder trials, insomnia and nervousness led to drug discontinuation in 1% and 0.1%, respectively, of the patients treated with Effexor XR up to 12 weeks.

Changes in Weight Adult Patients: A loss of 5% or more of body weight occurred in 7% of Effexor XR-treated and 2% of placebo-treated patients in the short-term placebo-controlled major depressive disorder trials. The discontinuation rate for weight loss associated with Effexor XR was 0.1% in major depressive disorder studies. In placebo-controlled GAD studies, a loss of 7% or more of body 15 Reference ID: 3537473 weight occurred in 3% of Effexor XR patients and 1% of placebo patients who received treatment for up to 6 months. The discontinuation rate for weight loss was 0.3% for patients receiving Effexor XR in GAD studies for up to eight weeks. In placebo-controlled Social Anxiety Disorder trials, 4% of the Effexor XR-treated and 1% of the placebo-treated patients sustained a loss of 7% or more of body weight during up to 6 months of treatment. None of the patients receiving Effexor XR in Social Anxiety Disorder studies discontinued for weight loss. In placebo-controlled panic disorder trials, 3% of the Effexor XR-treated and 2% of the placebo-treated patients sustained a loss of 7% or more of body weight during up to 12 weeks of treatment. None of the patients receiving Effexor XR in panic disorder studies discontinued for weight loss.

The safety and efficacy of venlafaxine therapy in combination with weight loss agents, including phentermine, have not been established. Co-administration of Effexor XR and weight loss agents is not recommended. Effexor XR is not indicated for weight loss alone or in combination with other products.



Pages:     | 1 | 2 || 4 | 5 |   ...   | 9 |


Similar works:

«A THEOLOGICAL EXAMINATION OF INWARDNESS IN THE FAITH AND PRACTICE OF BRITISH QUAKERS By CAROLE ANNE HAMBY A thesis submitted to the University of Birmingham for the degree of DOCTOR OF PHILOSOPHY Department of Theology and Religion College of Arts and Law The University of Birmingham October, 2015 University of Birmingham Research Archive e-theses repository This unpublished thesis/dissertation is copyright of the author and/or third parties. The intellectual property rights of the author or...»

«The Cob Builders Handbook You Can Hand-Sculpt Your Own Home Table Of Contents:  Acknowledgements and Warning INTRODUCTION What is cob? Why build with cob?DESIGNING YOUR HOME SWEET HOME! Things to do to get ready Think Small Think Rounded Make the Most of the Climate Design with passive solar access in mind Other things to think about when designing One Story or More? Noise Plan for Future Additions Now Designing the Entrance Buttresses Permits CHOOSING YOUR SITE Here's a list of some things...»

«PSYCHOLOGY HONOURS THESIS HANDBOOK Introduction Third and fourth year students majoring in psychology at York often ask for additional information about the Honours Thesis. The purpose of this handbook is to provide some of this information along with some useful advice about completing your thesis work. It is a good source of information, but it is not the only available source of information. If you have a question or a problem that pertains to your thesis work, you may consult a number of...»

«A CROSS-CULTURAL STUDY OF THE RELATIONSHIPS BETWEEN EPISTEMOLOGICAL BELIEFS AND MORAL JUDGMENT AS A PSYCHOLOGICAL FOUNDATION FOR MORAL EDUCATION by CHANGWOO JEONG (Under the Direction of RONALD L. VANSICKLE) ABSTRACT Contemporary research has examined relationships between individuals’ epistemological assumptions and their judgments about what is right, fair, and good. However, existing studies primarily have utilized interviews and a questionnaire method with U.S. college students, so less...»

«Some Psychological Consequences of the Anatomical Distinction between the Sexes by Sigmund Freud EDITOR'S NOTE: This paper was finished by August, 1925, when Freud showed it to Ferenczi. It was read on his behalf by Anna Freud at the Homburg International Psycho-Analytical Congress on September 3, and was published in the Zeitschrift later in the autumn. What is in effect a first complete re-assessment of Freud's views on the psychological development of women will be found condensed in this...»

«Public Broadcasters, the Internet, and Democracy Comparing Policy and Exploring Public Service Media Online Hallvard Moe Dissertation for the degree philosophiae doctor (PhD) University of Bergen Public Broadcasters, the Internet, and Democracy Comparing Policy and Exploring Public Service Media Online Bergen, 2008. Copyright: Hallvard Moe (Part I, and Part II, Article 1); Sage Publications (Part II, Article 2, 4, and 5); Intellect Books (Part II, Article 3). Public Broadcasters, the Internet,...»

«Gold Nanoparticles: Synthesis, Characterisation and their Effect on Pseudomonas Flourescens By Yusuf Nur A thesis submitted to The University of Birmingham for the Degree of DOCTOR OF PHILOSOPHY School of Geography, Earth and Environmental Sciences The University of Birmingham April 2013 I University of Birmingham Research Archive e-theses repository This unpublished thesis/dissertation is copyright of the author and/or third parties. The intellectual property rights of the author or third...»

«General-purpose localization of textured • • Image regions Rutb Rosenboltz· XeroxPARC 3333 Coyote Hill Rd. Palo Alto, CA 94304 Abstract We suggest a working definition of texture: Texture is stuff that is more compactly represented by its statistics than by specifying the configuration of its parts. This definition suggests that to fmd texture we look for outliers to the local statistics, and label as texture the regions with no outliers. We present a method, based upon this idea, for...»

«CHAPTER 1 Qualitative Research and Habits of Mind Story is far older than the art of science and psychology and will always be the elder in the equation no matter how much time passes. —Clarissa Pinkola Estes Women Who Run With the Wolves (1996) B ecause the researcher is the research instrument in qualitative research projects, it is important for the researcher to practice and refine techniques and habits of mind for qualitative research. Habits of mind in this text will include observation...»

«David Barlow and Panic Disorder 1 RUNNING HEAD: DAVID BARLOW AND PANIC DISORDER The Contribution of David Barlow to the Understanding and Treatment of Panic Disorder Brett J. Deacon, Ph.D.* Tamer I. Fawzy, M.A. University of Wyoming, Laramie, WY University of Wyoming, Department of Psychology, Dept. 3415, 1000 E. University Ave., Laramie, WY 82071, USA *Corresponding author, Tel: 1-307-766-3317, fax 1-307-766-2926 e-mail address: bdeacon@uwyo.edu David Barlow and Panic Disorder 2 The...»

«Intentional Binding and the Sense of Agency: A review James W. Moore1,2 & Sukhvinder S. Obhi3,4 1. Department of Psychology, Goldsmiths, University of London, London, UK 2. Brain Mapping Unit, Department of Psychiatry, University of Cambridge, Cambridge, UK 3. Centre for Cognitive Neuroscience & Department of Psychology, Wilfrid Laurier University, Waterloo, Ontario, Canada 4. Institute of Cognitive Neuroscience, University College London, London, U.K. Correspondence: sobhi@wlu.ca PrePrint...»

«Journal of Research in Personality 40 (2006) 472–481 www.elsevier.com/locate/jrp Informant reports: A cheap, fast, and easy method for personality assessment Simine Vazire * Department of Psychology, The University of Texas at Austin, Austin, TX 78712, USA Available online 21 November 2005 Abstract Despite widespread agreement that multi-method assessments are optimal in personality research, the literature is dominated by a single method: self-reports. This pattern seems to be based, at...»





 
<<  HOME   |    CONTACTS
2016 www.dissertation.xlibx.info - Dissertations, online materials

Materials of this site are available for review, all rights belong to their respective owners.
If you do not agree with the fact that your material is placed on this site, please, email us, we will within 1-2 business days delete him.